Active Substance: dibotermin alfa
Common Name: dibotermin alfa
ATC Code: M05BC01
Marketing Authorisation Holder: Medtronic BioPharma B.V.
Active Substance: dibotermin alfa
Authorisation Date: 2002-09-09
Therapeutic Area: Tibial Fractures Spinal Fusion Fracture Fixation, Internal
Pharmacotherapeutic Group: Drugs for treatment of bone diseases
Inductos is indicated for single-level (L4 - S1) anterior lumbar spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least six months of nonoperative treatment for this condition.
Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.
What is Inductos?
Inductos is a kit for implant. The kit consists of a powder containing the active substance, dibotermin alfa, a solvent and a matrix (collagen sponge).
What is Inductos used for?
Inductos is used to help new bone develop. It can be used in the following situations:
- lower-back spine-fusion surgery. This is a type of surgery used to relieve back pain due to a damaged disc where the disc between two vertebrae (the bones in the spine) is removed and the vertebrae are fused (joined) together. Inductos is used together with a special metal cage that corrects the position of the spine. In this type of surgery, Inductos can be used instead of an autogenous bone graft (bone taken from one part of a person’s body and placed in another part of the body). Inductos is used in adults who have been treated for at least six months for back pain due to a damaged disc but have not had an operation;
- surgery to heal fractures (breaks) of the tibia (shin bone). Inductos is used in addition to standard treatment and care. It is only used when the nail to fix the bone does not need ‘reaming’ (drilling to make room for nail placement).
The medicine can only be obtained with a prescription.
How is Inductos used?
Inductos should be used by a qualified surgeon. Inductos is made up into a solution before use, applied to the matrix and left for at least 15 minutes (but no more than two hours). The matrix is then cut, if needed, to the correct size before use. Generally one kit is sufficient. For lower-back spine fusion, the damaged disc between the vertebrae is removed and replaced with two metal cages filled with Inductos. The metal cages fix the position of the vertebrae, and Inductos encourages bone to grow between the two vertebrae to join them permanently in the correct position. For a fractured tibia, Inductos is placed around the broken bone to aid healing.
How does Inductos work?
The active substance in Inductos, dibotermin alfa, acts on the bone structure. It is a copy of a protein called bone morphogenetic protein 2 (BMP-2), which is produced naturally by the body and helps with the formation of new bone tissue. When implanted, dibotermin alfa stimulates the bone tissue around the matrix to make new bone. The newly formed bone grows into the matrix, which then degrades. Dibotermin alfa is produced by a method known as ‘recombinant DNA technology’: it is made by cells that have received a gene (DNA) which makes them able to produce dibotermin alfa. The replacement dibotermin alfa acts in same way as BMP-2 produced naturally by the body.
How has Inductos been studied?
Inductos has been studied in 279 patients having lower-back spine fusion. Spinal fusion using Inductos was compared with fusion using a bone graft removed from the hip during surgery. The main measure of effectiveness was fusion of the vertebrae confirmed by X‑ray, and improvement in the pain and disability reported by the patient, measured two years after surgery.
Inductos has been studied in 450 patients with a fractured tibia. Inductos was compared with standard care. The main measure of effectiveness was the number of patients who did not need further treatment for their fractured tibia (such as a bone graft or changes to the nail used to fix the bones together) in the year following surgery.
What benefit has Inductos shown during the studies?
In spinal fusion, Inductos was as effective as bone grafts. After two years, 57% of the patients treated with Inductos (69 out of 122) had responded to treatment, compared with 59% of the patients treated with a bone graft (78 out of 133).
In patients with a fractured tibia, using Inductos in addition to standard care was more effective than standard care alone in reducing the risk of treatment failure. Of the patients in the standard care group, 46% needed a further intervention within a year to repair their fracture, while the proportion was 26% for those also receiving Inductos.
What is the risk associated with Inductos?
The most common side effects with Inductos (seen in more than 1 patient in 10) are neuralgia (nerve pain) when used in spine surgery and localised infection when used in tibia-fracture surgery. The most severe side effect is localised oedema (swelling at the surgery site) when used in upper spine (neck) surgery. For the full list of all side effects reported with Inductos, see the package leaflet.
Inductos must not be used in people who are hypersensitive (allergic) to dibotermin alfa or any of the other ingredients. Inductos must also not be used in the following situations:
- patients who are still growing;
- patients diagnosed with or being treated for cancer;
- patients with an active infection at the surgery site;
- patients with an inadequate blood supply at the fracture site;
- treating a fracture that is related to a disease such as Paget’s disease or cancer.
Why has Inductos been approved?
The Committee for Medicinal Products for Human Use (CHMP) decided that Inductos’s benefits are greater than its risks for single-level (L4 - S1) anterior lumbar spine fusion as a substitute for autogenous bone graft and for the treatment of acute tibia fractures in adults, as an adjunct to standard care. The Committee recommended that Inductos be given marketing authorisation.
Other information about Inductos
The European Commission granted a marketing authorisation valid throughout the European Union for Inductos on 9 September 2002.
For more information about treatment with Inductos, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Source: European Medicines Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.